Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 7,046 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: High dose Clear all
Terminated Phase 2 Interventional Results available

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

NCT01886287
View directory record Official record
Conditions
Neuroendocrine Carcinoma
Interventions
Octreotide LAR
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2015 · Synced Oct 18, 2026, 2:42 AM EDT
Terminated Phase 2Phase 3 Interventional

Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

NCT00675714
View directory record Official record
Conditions
Burns
Interventions
Stable Isotope Infusion Study, Collection of blood and tissues, Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI, Humatrope, Ketoconazole, Oxandrolone, Propranolol, Oxandrolone and propranolol combined, Humatrope and propranolol combined, Placebo, Exercise--Hospital supervised intensive exercise program, Home exercise program
Procedure · Drug · Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 80 Years
Enrollment
1,126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 18, 2026, 2:42 AM EDT
Recruiting Phase 2 Interventional

A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

NCT04042844
View directory record Official record
Conditions
Lumbar Disc Disease
Interventions
BRTX-100, Saline
Biological · Drug
Lead sponsor
BioRestorative Therapies
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Santa Monica, California • Walnut Creek, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Phase 2 Interventional

Effect of High Dose Vitamin E on Carotid Atherosclerosis

NCT00010699
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Vitamin E
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
2
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2013 · Synced Oct 18, 2026, 2:42 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

tFUS to Enhance Alertness and Performance

NCT06461221
View directory record Official record
Conditions
Reaction Time, Alertness
Interventions
Transcranial Focused Ultrasound
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
22 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

NCT03254784
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
Interventions
BMS-986165 Capsule, BMS-986165 Tablet
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 18, 2026, 2:42 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Phase III Randomized Trial Comparing Stereotactic Body Radiation Therapy (SBRT) vs Conventional Palliative Radiation Therapy for Painful Bone Metastases

NCT06065449
View directory record Official record
Conditions
Bone Metastases
Interventions
Radiation Therapy
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 18, 2026, 2:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

NCT07020221
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
Interventions
VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab, Gemcitabine + Nab-paclitaxel, Pembrolizumab, Defactinib, Midazolam, Repaglinide
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 18, 2026, 2:42 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)

NCT00914758
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Washington Neuropsychology Research Group
Other
Eligibility
25 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
7
States / cities
Berkely, California • Lexington, Kentucky • Springfield, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2009 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Phase 3 Interventional

Citalopram in Treating Postmenopausal Women With Hot Flashes

NCT00363909
View directory record Official record
Conditions
Breast Cancer, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment
Interventions
citalopram hydrobromide, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
198
States / cities
Augusta, Georgia • Aurora, Illinois • Bloomington, Illinois + 126 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Oct 18, 2026, 2:42 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

NCT07477704
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
34
States / cities
Anniston, Alabama • Cullman, Alabama • Anaheim, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label Food Effect Study of Telotristat Etiprate

NCT02157584
View directory record Official record
Conditions
Healthy
Interventions
Telotristat etiprate
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Phase 1 Interventional

A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)

NCT04834778
View directory record Official record
Conditions
Renal Cell Carcinoma, Gastric Cancer, Metastatic Breast Cancer, Small-cell Lung Cancer, Other Solid Tumors
Interventions
HC-5404-FU
Drug
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Detroit, Michigan • Saint Paul, Minnesota • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

NCT04053634
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
84
States / cities
Surprise, Arizona • Little Rock, Arkansas • Los Angeles, California + 77 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 18, 2026, 2:42 AM EDT
Recruiting Early Phase 1 Interventional

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

NCT06637306
View directory record Official record
Conditions
Locally Advanced Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
Interventions
Dupilumab, Pembrolizumab, Paclitaxel, Carboplatin
Drug
Lead sponsor
Rima Patel
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Not applicable Interventional

OPTImizing Precision of Hypertension Care to Maximize Blood Pressure Control Pilot (OPTI-BP Pilot)

NCT02814552
View directory record Official record
Conditions
High Blood Pressure
Interventions
HTN PRA App, Blood Sample
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Macclenny, Florida • Old Town, Florida • Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients

NCT01359735
View directory record Official record
Conditions
Non-melanoma Skin Cancer
Interventions
HP802-247, Bacitracin Ointment
Biological
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 29, 2017 · Synced Oct 18, 2026, 2:42 AM EDT
Recruiting Early Phase 1 Interventional

Fibroblast Activating Protein (FAP) PET/CT in Adults With Tuberculosis

NCT07830771
View directory record Official record
Conditions
Tuberculosis, Pulmonary
Interventions
[18F]-FAPI-74
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Phase 4 Interventional Results available

Interventions for Children With Attention and Reading Disorders

NCT01133847
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Reading Disabilities
Interventions
Methylphenidate, Intensive reading instruction, Parent Training, Mixed Salt Amphetamine, Atomoxetine, Guanfacine
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
7 Years to 12 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

NCT04209855
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
78
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 18, 2026, 2:42 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

NCT04929236
View directory record Official record
Conditions
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Panzyga
Drug
Lead sponsor
Octapharma
Industry
Eligibility
2 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
6
States / cities
Birmingham, Alabama • Orange, California • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 18, 2026, 2:42 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

NCT05583149
View directory record Official record
Conditions
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL, Diffuse Large B-cell Lymphoma (DLBCL), De Novo or Transformed Indolent B-cell Lymphoma, DLBCL, Nos Genetic Subtypes, T Cell/Histiocyte-rich Large B-cell Lymphoma, EBV-Positive DLBCL, Nos, Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL), High-Grade B-Cell Lymphoma, Nos, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma, Grade 3b Follicular Lymphoma, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
Interventions
ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy
Drug
Lead sponsor
Patrick C. Johnson, MD
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 18, 2026, 2:42 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Detection of Cannabis Impairment With ISBRG's SpotLight-THC

NCT05276232
View directory record Official record
Conditions
Cannabis
Interventions
Cannabis(THC) inhaled
Drug
Lead sponsor
ISBRG Corp
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

NCT00001832
View directory record Official record
Conditions
Melanoma, Neoplasm Metastasis
Interventions
gp100:209-217 (210M), Montanide ISA-51, IL-2, MART-1:26-35(27L), Abl cells, Fludarabine, Cyclophosphamide, GCSF (Growth colony stimulating factor), Apheresis
Drug · Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
7 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 21, 2012 · Synced Oct 18, 2026, 2:42 AM EDT